What Entereg Treats: Main Uses and Benefits

The medication is commonly used to help with supporting the timely return of gastrointestinal function following surgeries that include partial bowel resection with primary anastomosis. The primary use is to address the condition of postoperative ileus (POI), which is the temporary lack of movement in the intestines that creates noticeable physiological strain after major abdominal surgery. Its use supports the digestive system in assisting with the management of symptoms related to gut stasis.

Entereg contributes to supporting progress toward timely recovery milestones. This involves assisting with the easing of recovery timeframes required to reach important physiological endpoints, such as the ability to tolerate solid food, and assisting with maintaining functional stability to support progression toward discharge status. The use is considered relevant in the acute clinical settings of Enhanced Recovery After Surgery (ERAS) protocols.

Quick Fact: Relief for Post-Surgical Gut Stasis
Main Use: Supporting the return of normal gut function following partial bowel resection.
Symptom Managed: Temporary lack of movement in the gut (POI) which creates functional strain.
Patient Benefit: Contributes to improved day-to-day comfort and a timely progression toward recovery milestones.

Eligibility Scope

Contraindicated Populations The use of Entereg (alvimopan) is strictly contraindicated in patients who have taken therapeutic doses of opioids for more than seven consecutive days immediately prior to starting treatment. This absolute prohibition, as defined by regulatory documents, also extends to individuals with a known hypersensitivity to alvimopan or any of its components.

Restricted and Not Recommended Use Official labeling states that the medicine is not recommended for several populations due to potential risk or insufficient data. This includes individuals with severe hepatic impairment (Child-Pugh Class C) and those with end-stage renal disease. Use is also not recommended in patients with a complete gastrointestinal obstruction or those undergoing surgery involving pancreatic or gastric anastomosis.

Conditional and Age-Related Rules Eligibility is limited to hospitalized adults through a restricted program (REMS), and therapy must not exceed a total of 15 doses or seven days. While older adults (geriatric patients) are eligible without dose adjustment, safety and effectiveness have not been established in pediatric patients. Patients with mild-to-moderate hepatic or renal impairment may be eligible but require close monitoring.

️ Interaction-Related Restrictions

Entereg is contraindicated in patients who have received therapeutic doses of opioid agonists for more than seven consecutive days immediately prior to therapy. This is an official restriction noted due to the risk of increased gastrointestinal adverse reactions in opioid-tolerant patients.

Use is not recommended in two specific populations: patients with severe hepatic impairment (Child-Pugh Class C) and patients with end-stage renal disease (ESRD). This restriction is based on the documented risk of significantly increased plasma exposure in these populations, which is an intrinsic, population-dependent interaction consideration.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance/Condition	Official Regulatory Statement
Transporter-Mediated	P-glycoprotein (P-gp) Inhibitors	May increase the systemic plasma exposure (levels) of alvimopan, as the drug is a P-gp substrate.
Metabolic Pathway	CYP Enzymes (Inhibitors/Inducers)	Officially documented as unlikely to alter the metabolism of alvimopan, which is not a substrate of major CYP enzymes.
Pharmacodynamic	Other PAMORAs	Carries a potential for additive peripheral mu-opioid receptor antagonism.
Food Influence	High-Fat Meal	Reduces both maximum concentration ( C max) and total exposure ( AUC), but no mandatory administration timing rule is stated.

The official interaction profile is defined by the duration-based opioid restriction and the pharmacokinetic risks associated with P-gp transport inhibition and existing organ impairment, ensuring all constraints are strictly tied to regulatory labeling.

Competitive Antagonism at Peripheral mu-Opioid Receptors

The primary mechanism of action involves alvimopan acting as a selective competitive antagonist at the mu-opioid receptor (MOR). This molecular interaction occurs on the peripheral MORs within the enteric wall. By binding to the receptor without activating it, the drug blocks the inhibitory signaling that reduces muscular contraction.

Restoration of Enteric Nervous System Function

The blockade of peripheral mu-opioid receptors removes the inhibitory effects of both exogenous and endogenous opioids on the gut's intrinsic nerve network, the Enteric Nervous System (ENS). This allows the ENS to resume propulsive signaling, resulting in coordinated muscular contractions (peristalsis).

Mechanistic Guarantee of Peripheral Selectivity

Alvimopan is structurally engineered to be a peripherally acting compound; its large, zwitterionic structure and interaction with efflux pumps limit its ability to cross the Blood-Brain Barrier (BBB). This mechanism is crucial because it ensures the drug selectively reverses opioid-induced reduction of GI transit while leaving centrally mediated mu-opioid receptor activity unaffected.

The administration of Entereg (alvimopan) is governed by a fixed, oral, and highly constrained short-term protocol established for use solely within a hospital setting. The medication is always administered as a 12 mg oral capsule.

---

The treatment plan is structured around the time of surgery, beginning with a single 12 mg initial dose taken orally between 30 minutes to 5 hours prior to the scheduled procedure. The maintenance phase starts on the day immediately following surgery, continuing with a 12 mg dose taken twice daily (q12hr). The capsule may be taken with or without food.

---

The total duration of use is strictly limited. The treatment course is capped at a total of 15 doses, or a maximum of seven consecutive days, whichever limit is reached first. Due to this defined, acute treatment context, the medicine is exclusively restricted to the inpatient setting and is prohibited from being dispensed for continuation after a patient is discharged.

Usage is characterized for specific patient groups. No dosage adjustment is necessary when Entereg is used in older adult patients. Similarly, no modification to the standard dose is required for patients presenting with mild or moderate kidney or liver impairment.

Research Evidence Overview of Studies for Entereg

---

Evidence for Gastrointestinal Recovery after Bowel Resection

The primary research for alvimopan (Entereg) was studied in trials involving patients undergoing specific types of abdominal procedures, specifically partial small or large bowel resection with primary anastomosis. The research in this setting includes multiple large-scale randomized controlled trials (RCTs) that examined outcomes related to physical discomfort and daily functioning. These short-term, double-blind studies were designed to track how quickly the gastrointestinal (GI) tract regains its normal function in the acute period immediately following surgery.

In these trials, studies tracked functional outcomes reflecting daily functioning. Key endpoints included the time to first tolerated solid food and the time to first bowel movement. Pooled analyses of the data describe patterns related to the measured time to reach these GI recovery endpoints. Research also examined measurements of functional outcomes reflecting daily functioning and activity level, such as the time until the hospital discharge order was written (DCO).

---

Duration of Evidence and Long-Term Follow-up

The existing evidence base for Entereg is strictly limited to short-term, acute use. The medication was studied only for administration during the immediate post-operative period, typically up to a maximum of seven days or 15 doses. Consequently, the research provides insight into short-term changes. Long-term effects are not fully established, and long-term outcomes are not well characterized by the available clinical trials. Study results reflect the specific conditions under which they were conducted and describe group patterns, not personal outcomes.

---

Areas of Research Uncertainty and Study Limitations

The evidence quality varies across studies when considering contexts outside the narrow indication of bowel resection. Specifically, data for other abdominal procedures are still emerging. The research also highlights that measured endpoints are not fully established for all surgical approaches or complex patient types. For example, patients requiring recent or long-term therapeutic opioid use prior to surgery were generally excluded from the pivotal trials, meaning data for these specific patient groups remain insufficient.

Key Studies & References

1. Alvimopan for postoperative ileus following abdominal surgery: a systematic review (2024)

Common questions about Entereg (FAQ)

Q: Is Entereg the same type of medicine as a regular laxative?

A: Entereg is classified as a Peripherally Acting μ-Opioid Receptor Antagonist (PAMORA). This means it works by blocking certain receptors located only in the gut, which helps restore the natural muscular contractions (peristalsis) in the digestive tract. This specific mechanism of action is different from how most common osmotic or stimulant laxatives work.

Q: Are there any specific foods or drinks that should be avoided while using Entereg?

A: According to official product information, Entereg may be taken either with or without food. While studies show that consuming a high-fat meal can slightly reduce the amount of medicine absorbed into the body, there are no mandatory food restrictions listed in the administration instructions.

Q: Is Entereg still being studied or is the research finished?

A: The major clinical trials that led to the drug's approval for its specific indication are complete. However, the official evidence base is strictly focused on short-term, acute use. Documents indicate that data for other abdominal procedures are still emerging.

Q: How does Entereg differ from other opioid receptor antagonists?

A: Entereg is designed to be a peripherally acting medication. Its chemical structure limits its ability to cross the blood-brain barrier (BBB). This specific design ensures that the medication works primarily on the gut to help restore function without interfering with the patient's pain relief that is mediated in the central nervous system.

Q: What does 'opioid-naïve' mean in the context of being able to take Entereg?

A: The use of Entereg is contraindicated, or prohibited, for patients who have received therapeutic doses of opioid pain medicines for more than seven consecutive days immediately before treatment. This exclusion criterion defines a population where the medicine is prohibited. The regulatory status applies to individuals outside this prohibited group.

Q: Are the side effects of Entereg mild or serious in most people?

A: The official documentation lists several common adverse reactions for Entereg, such as flatulence and constipation. However, official safety considerations also highlight a reported, but unestablished, risk of myocardial infarction observed in a separate, long-term study, which is the reason the drug is restricted to short-term, inpatient use.

Q: Does the medication speed up the time it takes for a person to pass gas?

A: The medication is intended to restore coordinated muscular contractions (peristalsis) in the gut. Clinical studies primarily assessed the effectiveness of Entereg by tracking the time to first tolerated solid food and the time to first bowel movement following surgery and the start of treatment.

Q: How long after taking Entereg should the bowels start moving?

A: Clinical studies assessed the effectiveness of the treatment by tracking the time to first tolerated solid food and the time to first bowel movement after surgery and the initiation of treatment. Official results summarize patterns related to the measured time for patients, as a group, to reach these recovery endpoints.

Q: How long does Entereg stay in your system after the final pill?

A: According to official pharmacokinetic information, the terminal half-life for alvimopan is described as approximately 10 to 17 hours. The half-life for its major active metabolite in the body is around 10 to 18 hours.

Q: Why does the official drug information mention a possible cancer risk?

A: The official prescribing information notes that non-clinical toxicology studies reported an increased incidence of tumors in mice and rats. These animal studies are typically conducted over the animals' full lifespans. This finding is a standard part of the regulatory review process for medicines and is included in the official documentation.

Q: Can Entereg be taken at the same time as my regular anti-nausea medication?

A: The official interaction profile notes that taking Entereg with medicines that inhibit a transporter protein called P-glycoprotein (P-gp) may increase the levels of alvimopan in the bloodstream. If an anti-nausea medication is a known P-gp inhibitor, the determination of its effect on P-gp status is part of the clinical assessment.

Q: Does Entereg interact with over-the-counter pain relievers like Tylenol or Advil?

A: Official documentation states that it is unlikely to alter the metabolism of alvimopan because the medicine is not significantly processed by the body’s major CYP enzymes. As a result, there are no documented interactions with over-the-counter pain relievers such as acetaminophen (Tylenol) or ibuprofen (Advil) in the official labeling.

Q: Does Entereg affect how other medications for heart conditions work?

A: The official profile focuses on the risk associated with a protein transporter called P-glycoprotein (P-gp). Medicines that inhibit P-gp (which includes some heart medications) may cause an increase in the systemic plasma exposure (levels) of alvimopan.

Q: Can the Entereg tablet be crushed or chewed if a patient has trouble swallowing?

A: The medication is manufactured and supplied only as an oral capsule. The official prescribing information for Entereg does not contain instructions that permit or prohibit crushing, chewing, or otherwise altering the capsule for consumption.

Q: Is Entereg useful for patients recovering from non-bowel related surgeries?

A: The medication is only approved for use to accelerate the recovery of bowel function following specific types of small or large bowel resection surgery. The safety and efficacy of using Entereg for patients recovering from other types of surgeries have not been established in clinical trials.

How to Store and Dispose of Entereg (alvimopan)

Entereg capsules must be stored according to regulatory standards to maintain stability and integrity.

Storage Requirements

Storage Condition	Requirement
Temperature	Store at 25 C (77 F), consistent with USP Controlled Room Temperature.
Excursions	Permitted between 15 C to 30 C (59 F to 86 F).

Handling and Disposal

The distribution and use of Entereg are restricted to hospitals enrolled in the E.A.S.E. REMS Program. The medication is only for short-term, inpatient use and is not dispensed to outpatients. Therefore, all handling and disposal are managed at the institutional level.

Unused or expired Entereg must be disposed of by the hospital facility according to its established internal protocols for pharmaceutical waste management, ensuring the product does not leave the registered facility.